Prestige Consumer Healthcare Inc. (NYSE:PBH) Given Average Rating of “Moderate Buy” by Analysts

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) have been given an average rating of “Moderate Buy” by the four ratings firms that are currently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $85.25.

A number of analysts have weighed in on PBH shares. Sidoti cut Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price objective for the company. in a research report on Monday, December 9th. DA Davidson reissued a “buy” rating and issued a $95.00 price objective on shares of Prestige Consumer Healthcare in a research note on Monday, November 11th. StockNews.com downgraded shares of Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research report on Tuesday. Finally, Jefferies Financial Group restated a “hold” rating and set a $76.00 target price (up from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th.

Insider Buying and Selling at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, CEO Ronald M. Lombardi sold 10,875 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total transaction of $898,275.00. Following the sale, the chief executive officer now directly owns 320,952 shares of the company’s stock, valued at $26,510,635.20. This trade represents a 3.28 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Adel Mekhail sold 9,063 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $82.00, for a total transaction of $743,166.00. Following the completion of the sale, the executive vice president now directly owns 18,365 shares of the company’s stock, valued at $1,505,930. The trade was a 33.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 38,810 shares of company stock worth $3,187,300. 1.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. OLD National Bancorp IN purchased a new position in shares of Prestige Consumer Healthcare in the 2nd quarter valued at $262,000. QRG Capital Management Inc. increased its stake in Prestige Consumer Healthcare by 4.7% during the 2nd quarter. QRG Capital Management Inc. now owns 5,397 shares of the company’s stock worth $372,000 after buying an additional 242 shares during the period. ORG Partners LLC acquired a new position in shares of Prestige Consumer Healthcare in the 2nd quarter valued at approximately $39,000. Robbins Farley raised its stake in shares of Prestige Consumer Healthcare by 7.7% in the 2nd quarter. Robbins Farley now owns 31,480 shares of the company’s stock valued at $2,167,000 after purchasing an additional 2,240 shares in the last quarter. Finally, Blue Trust Inc. raised its position in shares of Prestige Consumer Healthcare by 106.9% during the 2nd quarter. Blue Trust Inc. now owns 867 shares of the company’s stock valued at $63,000 after acquiring an additional 448 shares in the last quarter. Institutional investors and hedge funds own 99.95% of the company’s stock.

Prestige Consumer Healthcare Stock Performance

Shares of Prestige Consumer Healthcare stock opened at $82.26 on Monday. The firm’s fifty day simple moving average is $77.85 and its 200-day simple moving average is $72.35. Prestige Consumer Healthcare has a 12 month low of $57.95 and a 12 month high of $86.36. The stock has a market capitalization of $4.06 billion, a price-to-earnings ratio of 20.02, a PEG ratio of 2.35 and a beta of 0.49. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.56 and a quick ratio of 2.10.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings data on Thursday, November 7th. The company reported $1.09 EPS for the quarter, meeting analysts’ consensus estimates of $1.09. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The company had revenue of $283.79 million for the quarter, compared to analyst estimates of $282.09 million. During the same period in the previous year, the business posted $1.07 earnings per share. Prestige Consumer Healthcare’s quarterly revenue was down .9% on a year-over-year basis. As a group, equities analysts forecast that Prestige Consumer Healthcare will post 4.44 earnings per share for the current year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.